Ipilimumab/nivolumab Reactions 1680, p191 - 2 Dec 2017 Hyperthyroidism, hypothyroidism and hypophysitis : 9 case reports In a retrospective study, 9 patients (4 men and 5 women; aged 50–76-years) were described, who developed hyperthyroidism, hypothyroidism or hypophysitis during treatment with nivolumab alone or nivolumab and ipilimumab [not all dosages stated; routes not stated]. The patients, who had metastatic renal cell carcinoma (1 patient), multiple myeloma (2 patients), metastatic lung cancer (2 patients), metastatic bladder cancer (1 patient), metastatic oesophageal cancer (1 patient) or metastatic melanoma (2 patients), were started on monotherapy with nivolumab 3 mg/kg (6 patients) or nivolumab 1 mg/kg and ipilimumab (2 patients) or nivolumab 1mg/kg for three months followed by 3 mg/kg and ipilimumab (1 patient). Time to first detection of abnormal thyroid blood test after initiation of treatment was 21–249 days. The Anti-TPO antibody was positive in 3 patients (patient 2,5 and 9). The Anti-TG antibody was positive in 5 patients (patient 2,3,4,5 and 7). The TSH levels were less than 0.4 µIU/mL to 56 µIU/mL (ref: more than 0.4 to less than 4.2 µIU/mL). Three patients (patient 1,2 and 7) initially developed hyperthyroidism and then hypothyroidism. Patient 6 and 8 developed only hyperthyroidism and patient 6 was lost to follow-up. The patient 8 also developed hypophysitis, while his hyperthyroidism recovered spontaneously. The remaining four patients developed only hypothyroidism (Patient 3,4,5 and 9) [not all outcomes stated]. Author comment: "The most common endocrine complication observed with [ipilimumab] is hypophysitis, while the most common endocrinopathy reported with PD-1 inhibitors is thyroid disease" "Combination therapy with a PD-1 inhibitor and [ipilimumab] may increase the risk of thyroid disease compared with [nivolumab] alone, as has been reported previously in clinical trials" O’Malley G, et al. RAPID EVOLUTION of THYROID DYSFUNCTION in PATIENTS TREATED with NIVOLUMAB. Endocrine Practice 23: 1223-1231, No. 10, Oct 2017. Available from: URL: http://doi.org/10.4158/EP171832.OR - USA 803284675 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial